Exelixis, Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer

Jan 07, 2008 - Exelixis, Inc. (Nasdaq: EXEL) announced that it has initiated a phase 1/2 trial of XL184 in patients with non-small cell lung cancer (NSCLC) who have had progressive disease while on a regimen containing erlotinib.XL184 is a small molecule that simultaneously inhibits the MET, RET and VEGFR receptor tyrosine kinases. In the initial phase 1 part of the study, safety and pharmacokinetics of combining XL184 with erlotinib will be evaluated. The primary endpoint of the phase 2 part of the study is overall response rate. Secondary endpoints include progression-free survival, overall survival and pharmacodynamics... Exelixis' Press Release-

Exelixis, Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer

Calif., Oct. 8 , 2007 - Exelixis, Inc. (Nasdaq: EXEL ) announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Fran cisco... Exelixis' Press Release -

Exelixis Submits XL880 Diligence Report to GlaxoSmithKline

Sept. 14, 2007- Exelixis, Inc. (Nasdaq: EXEL) announced that the company has submitted a comprehensive data report relating to XL880 to GlaxoSmithKline (GSK)...

XL880 has attractive pharmaceutical properties, with high solubility and oral bioavailability. In preclinical studies, XL880 inhibited its targets with nanomolar potency, and retained potent activity against mutationally activated forms of MET found in hereditary papillary renal cell carcinomas. The compound also demonstrated dose-dependent tumor growth inhibition in models of breast cancer, colorectal cancer, non-small cell lung cancer, and glioblastoma, and has been shown to cause substantial tumor regression in all models tested...

Exelixis' Press Release -